What are the cardiovascular benefits of tirzepatide (Mounjaro) in adults with type 2 diabetes who have established cardiovascular disease or high cardiovascular risk?

Cardiovascular Benefits of Mounjaro (Tirzepatide)

Tirzepatide demonstrates cardiovascular benefit in adults with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD) or multiple cardiovascular risk factors, with the most recent high-quality evidence showing noninferiority to dulaglutide (a proven GLP-1 RA) for major adverse cardiovascular events (MACE), and additional benefits including significant reductions in cardiometabolic risk factors. 1

Evidence for Cardiovascular Outcomes

The SURPASS-CVOT trial (2025), the most recent and highest-quality cardiovascular outcomes trial for tirzepatide, enrolled 13,165 patients with type 2 diabetes and established ASCVD. 1 This study demonstrated:

• Noninferiority to dulaglutide for the primary composite endpoint of cardiovascular death, myocardial infarction, or stroke (12.2% vs 13.1%; HR 0.92,95.3% CI 0.83-1.01) 1
• The trial narrowly missed statistical superiority (p=0.09), suggesting a trend toward benefit 1
• Patients had mean age 64 years, mean diabetes duration 14.7 years, and mean BMI 32.6 kg/m² 1

Earlier evidence from SURPASS-4 (2021) in 1,995 patients with type 2 diabetes and high cardiovascular risk showed that tirzepatide did not increase cardiovascular risk compared to insulin glargine, with adjudicated MACE-4 events (cardiovascular death, MI, stroke, hospitalization for unstable angina) occurring less frequently with tirzepatide (HR 0.74,95% CI 0.51-1.08). 2

Guideline-Based Recommendations

The 2025 American Diabetes Association Standards of Care explicitly recommend GLP-1 receptor agonists with demonstrated cardiovascular benefit for patients with type 2 diabetes and established ASCVD or multiple ASCVD risk factors to reduce MACE. 3 While tirzepatide is technically a dual GIP/GLP-1 receptor agonist rather than a pure GLP-1 RA, its cardiovascular safety profile and mechanistic similarities position it within this therapeutic class for cardiovascular risk reduction.

Key guideline recommendations applicable to tirzepatide: 3

• Use in patients with established ASCVD (prior MI, ischemic stroke, unstable angina, revascularization procedures)
• Use in high-risk patients aged ≥55 years with coronary/carotid/peripheral artery stenosis >50%, left ventricular hypertrophy, eGFR <60 mL/min/1.73m², or albuminuria
• Consider combination therapy with SGLT2 inhibitors for additive cardiovascular and kidney benefits

Cardiometabolic Risk Factor Improvements

Beyond direct cardiovascular outcomes, tirzepatide produces substantial improvements in multiple cardiometabolic risk factors that translate to reduced cardiovascular risk: 4

• Metabolic syndrome resolution: 72% reduction in odds of metabolic syndrome (OR 0.28,95% CI 0.24-0.33) 4
• Body weight: Significant reductions across all doses, with 96% reduction in odds of elevated BMI (OR 0.04,95% CI 0.02-0.08) 4
• Blood pressure: Consistent reductions observed in clinical trials 5, 2
• Lipid profiles: Improvements in triglycerides and HDL cholesterol 4
• Glycemic control: HbA1c reductions of 2.4-2.6% at 52 weeks 2

A 2024 meta-analysis including tirzepatide and GLP-1 RAs demonstrated 13% reduction in MACE (OR 0.87,95% CI 0.81-0.94), 12% reduction in all-cause mortality (OR 0.88,95% CI 0.82-0.96), and 12% reduction in cardiovascular mortality (OR 0.88,95% CI 0.80-0.96), with no significant differences between GLP-1 RAs and tirzepatide. 6

Kidney Protection

Tirzepatide demonstrates kidney-protective effects that contribute to overall cardiovascular benefit: 7

• Albuminuria reduction: 31% reduction in UACR in patients with type 2 diabetes at week 72 (95% CI -40.9 to -19.7) 7
• More pronounced effects in patients with baseline UACR ≥30 mg/g, with 55% reduction (95% CI -68.5 to -36.4) 7
• No adverse changes in eGFR, with potential improvements based on cystatin-C measurements 7

Mechanism of Cardiovascular Benefit

Tirzepatide's dual GIP/GLP-1 receptor agonism provides cardiovascular protection through multiple mechanisms: 8, 9

• Enhanced glucose-dependent insulin secretion and reduced glucagon levels 8
• Reduced inflammation and improved endothelial integrity 5, 9
• Delayed gastric emptying and reduced postprandial glucose excursions 8
• Significant weight reduction and improved insulin sensitivity 8

Clinical Application Algorithm

For patients with type 2 diabetes, prescribe tirzepatide when: 3, 1

1. Established ASCVD is present (prior MI, stroke, revascularization, documented coronary/carotid/peripheral artery disease)
2. High cardiovascular risk exists (age ≥55 years with arterial stenosis >50%, LVH, eGFR <60, or albuminuria)
3. Metabolic syndrome components are present alongside diabetes, particularly elevated BMI and multiple risk factors 4

Initiate independently of baseline HbA1c or HbA1c target, as cardiovascular benefit is the primary indication in these populations. 3

Important Caveats

• Gastrointestinal adverse events (nausea 12-23%, diarrhea 13-22%, vomiting 5-9%) are more common than with comparators but typically mild-to-moderate and occur during dose escalation 1, 2
• Hypoglycemia risk is lower with tirzepatide (6-9%) compared to insulin glargine (19%), particularly in patients not taking sulfonylureas 2
• The SURPASS-CVOT trial demonstrated noninferiority but not definitive superiority for MACE reduction compared to dulaglutide 1
• Ongoing SURMOUNT-MMO trial will provide definitive evidence for cardiovascular outcomes in obesity without diabetes 10